Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of Receivables data on file, last reported at $2.1 million in Q4 2024.

• On a quarterly basis, Receivables rose 290.32% year-over-year to $2.1 million in Q4 2024; TTM through Dec 2024 was $2.1 million, a 290.32% increase from a year earlier, with the FY2024 full-year figure at $2.1 million, up 290.32% from the prior year.
• Receivables for Q4 2024 stood at $2.1 million, up from $537000.0 in the prior quarter.
• Over the last five years, Receivables for FULC reached as high as $3.6 million in Q4 2021 and fell as low as $229000.0 in Q4 2022.
• Historically, Receivables has averaged $1.2 million across 5 years, with a median of $802500.0 in 2022.
• Across the five-year window, Receivables sank 93.7% in 2022 and surged 290.32% in 2024, its largest moves.
• Year by year, Receivables stood at $2.0 million in 2020, then jumped by 81.85% to $3.6 million in 2021, then sank by 93.7% to $229000.0 in 2022, then soared by 134.5% to $537000.0 in 2023, then jumped by 290.32% to $2.1 million in 2024.
• Per Business Quant data, the three most recent Receivables figures were $2.1 million in Q4 2024, $537000.0 in Q4 2023, and $580000.0 in Q3 2023.